Tuberculosis burning issues: Multidrug resistance and HIV-coinfection

Critical Reviews in Microbiology

Volumn 38, Issue 4, 2012, Pages 267-275

  Janbaz, Khalid Hussain ^a   Qadir, M Imran ^b   Ahmad, Bashir ^a   Sarwar, Abida ^b   Yaqoob, Nazish ^b   Masood, Muhammad Irfan ^c  

^a BAHAUDDIN ZAKARIYA UNIVERSITY   (Pakistan)

^b GC UNIVERSITY   (Pakistan)

^c UNIVERSITY OF VETERINARY AND ANIMAL SCIENCES   (Pakistan)

Author keywords

HIV coinfection; Multidrug resistance; Tuberculosis

Indexed keywords

AMIKACIN; CAPREOMYCIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; MACROLIDE; MULTIDRUG RESISTANCE PROTEIN; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFAMPICIN; RIFAMYCIN; RIFAPENTINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STREPTOMYCIN;

AFRICA; ANTIVIRAL THERAPY; CHINA; DIRECTLY OBSERVED THERAPY; EUROPEAN UNION; EXTRAPULMONARY TUBERCULOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIXED INFECTION; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PATHOGENESIS; PREGNANT WOMAN; PREVALENCE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; TUBERCULOSIS; UNITED STATES;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANIMALS; ANTITUBERCULAR AGENTS; COINFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

MYCOBACTERIUM TUBERCULOSIS;

EID: 84866980713     PISSN: 1040841X     EISSN: 15497828     Source Type: Journal    
DOI: 10.3109/1040841X.2012.664539     Document Type: Review

References (70)

1. Akolo C, Adetifa I, Shepperd S, Volmink J. (2010). Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev, 1, CD000171.
2. Albert H, Bwanga F, Mukkada S, Nyesiga B, Ademun JP, Lukyamuzi G, Haile M, Hoffner S, Joloba M, O'Brien R. (2010). Rapid screening of MDR-TB using molecular Line Probe Assay is feasible in Uganda. BMC Infect Dis, 10, 41.
3. Bass JB Jr, Farer LS, Hopewell PC, O'Brien R, Jacobs RF, Ruben F, Snider DE Jr, Thornton G. (1994). Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention. Am J Respir Crit Care Med, 149, 1359-1374.
4. Calver AD, Falmer AA, Murray M, Strauss OJ, Streicher EM, Hanekom M, Liversage T, Masibi M, van Helden PD, Warren RM, Victor TC. (2010). Emergence of increased resistance and extensively drugresistant tuberculosis despite treatment adherence, South Africa. Emerging Infect Dis, 16, 264-271.
5. CDC. (1996). Clinical update: impact of HIV protease inhibitors on the treatment of HIV-infected tuberculosis patients with rifampin. MMWR, 45, 921-925.
6. CDC. (1997). Anergy skin testing and tuberculosis preventive therapy for HIV-infected persons: revised recommendations. Centers for Disease Control and Prevention. MMWR Recomm Rep, 46, 1.
7. CDC. (2000a). Targeted tuberculin testing and treatment of latent tuberculosis infection. This Official Statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This Statement was endorsed by the Council of the Infectious Diseases Society of America (IDSA), September 1999, and the sections of this Statement as it relates to infants and children were endorsed by the American Academy of Pediatrics (AAP), August 1999. Am J Respir Crit Care Med, 161, S221.
8. CDC. (2000b). Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIVinfected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors. MMWR Morb Mortal Wkly Rep, 49, 185.
9. Chaisson RE, Martinson NA. (2008). Tuberculosis in Africa-combating an HIV-driven crisis. N Engl J Med, 358, 1089.
10. Chiang CY, Centis R, Migliori GB. (2010). Drug-resistant tuberculosis: past, present, future. Respirology, 15, 413-432.
11. Chikamatsu K, Mizuno K, Yamada H, Mitarai S. (2009). Cross-resistance between rifampicin and rifabutin among multi-drug resistant Mycobacterium tuberculosis strains. Kekkaku, 84, 631-633.
12. Cobelens FG, Egwaga SM, van Ginkel T, Muwinge H, Matee MI, Borgdorff MW. (2006). Tuberculin skin testing in patients with HIV infection: limited benefit of reduced cutoff values. Clin Infect Dis, 43, 634-639.
13. Dartois V, Barry CE. (2006). Clinical pharmacology and lesion penetrating properties of second-and third-line antituberculous agents used in the management of multidrug-resistant (mdr) and extensively-drug resistant (xdr) tuberculosis. Kekkaku, 81(11), 693-707.
14. Deodhar L, Miskeen P, Chomal S. (1999). Drug resistance in tuberculosis. BHJ, 41, 253.
15. Dey AB, Nagarkar K. (1995). Multi drug resistant tuberculosis. Trop Gastroenterol, 16, 92-100.
16. Doucet-Populaire F, Buriánková K, Weiser J, Pernodet JL. (2002). Natural and acquired macrolide resistance in mycobacteria. Curr Drug Targets Infect Disord, 2, 355-370.
17. Drobniewski F, Balabanova Y, Coker R. (2002). Clinical features, diagnosis, and management of multiple drug-resistant tuberculosis since 2002. Curr Opin Pulm Med, 10, 211-217.
18. Ehsan O, Qadir MI, Malik SA, Abbasi WS, Ahmad B. (2012). Efficacy of nanogold-insulin as a hypoglycemic agent. J Chem Soc Pak.
19. Elzi L, Schlegel M, Weber R, Hirschel B, Cavassini M, Schmid P, Bernasconi E, Rickenbach M, Furrer H; Swiss HIV Cohort Study. (2007). Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission. Clin Infect Dis, 44, 94-102.
20. Frieden TR, Sterling T, Pablos-Mendez A, Kilburn JO, Cauthen GM, Dooley SW. (1993). The emergence of drug-resistant tuberculosis in New York City. N Engl J Med, 328, 521-526.
21. Goldfeld A, Ellner JJ. (2007). Pathogenesis and management of HIV/TB co-infection in Asia. Tuberculosis (Edinb), 87 Suppl 1, S26-S30.
22. Golub JE, Saraceni V, Cavalcante SC, Pacheco AG, Moulton LH, King BS, Efron A, Moore RD, Chaisson RE, Durovni B. (2007). The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS, 21, 1441-1448.
23. Greenwood D. (1998). Resistance to antimicrobial agents: a personal view. J Med Microbiol, 47, 751-755.
24. Grobusch MP. (2010). Drug-resistant and extensively drug-resistant tuberculosis in southern Africa. Curr Opin Pulm Med, 16, 180-185.
25. Horsburgh CR Jr. (2004). Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med, 350, 2060-2067.
26. Hu Y, Hoffner S, Jiang W, Wang W, Xu B. (2010). Extensive transmission of isoniazid resistant M. tuberculosis and its association with increased multidrug-resistant TB in two rural counties of eastern China: a molecular epidemiological study. BMC Infect Dis, 10, 43.
27. Hussain A, Khalid SH, Qadir MI, Massud A, Ali M, Khan IU, Saleem M, Iqbal MS, Asghar S, Gul H. (2011). Water uptake and drug release behaviour of methyl methacrylate-co-itaconic acid [P(MMA/IA)] hydrogels cross-linked with methylene bis-acrylamide. J Drug Delvr Sci Tech, 21(3), 249-255.
28. Iseman MD. (1993). Treatment of multidrug-resistant tuberculosis. N Engl J Med, 329, 784-791.
29. Jain A, Dixit P. (2008). Multidrug-resistant to extensively drug resistant tuberculosis: what is next? J Biosci, 33, 605-616.
30. Javed F, Qadir MI, Janbaz KH, Ali M. (2011). Novel drugs from marine microorganisms. Crit Rev Microbiol, 37, 245-249.
31. Jayaswal S, Kamal MA, Dua R, Gupta S, Majumdar T, Das G, Kumar D, Rao KV. (2010). Identification of host-dependent survival factors for intracellular Mycobacterium tuberculosis through an siRNA screen. PLoS Pathog, 6, e1000839.
32. Jones KD, Hesketh T, Yudkin J. (2008). Extensively drug-resistant tuberculosis in sub-Saharan Africa: an emerging public-health concern. Trans R Soc Trop Med Hyg, 102, 219-224.
33. Karamat KA, Hayat S, Butt T, Abbasi S. (2000). Multi-drug resistant tuberculosis. Pak Armed Forces Med J, 50(2), 114-116.
34. Kim DH, Kim HJ, Park SK, Kong SJ, Kim YS, Kim TH, Kim EK, Lee KM, Lee SS, Park JS, Koh WJ, Lee CH, Shim TS. (2010). Treatment outcomes and survival based on drug resistance patterns in multidrug-resistant tuberculosis. Am J Respir Crit Care Med, 182, 113-119.
35. Ködmön C, Hollo V, Huitric E, Amato-Gauci A, Manissero D. (2010). Multidrug and extensively drug-resistant tuberculosis: a persistent problem in the European Union European Union and European Economic Area. Euro Surveill, 15(11), pii 19519.
36. Konings WN, Poelarends GJ. (2002). Bacterial multidrug resistance mediated by a homologue of the human multidrug transporter P-glycoprotein. IUBMB Life, 53, 213-218.
37. Lai CC, Tan CK, Lin SH, Liao CH, Huang YT, Chou CH, Hsu HL, Wang CY, Lin HI, Hsueh PR. (2010). Clinical and genotypic characteristics of extensively drug-resistant and multidrug-resistant tuberculosis. Eur J Clin Microbiol Infect Dis, 29, 597-600.
38. Laing RO, McGoldrick KM. (2000). Tuberculosis drug issues: prices, fixed-dose combination products and second-line drugs. Int J Tuberc Lung Dis, 4, S194-S207.
39. Loddenkemper R, Hauer B. (2010). Drug-resistant tuberculosis: a worldwide epidemic poses a new challenge. Dtsch Arztebl Int, 107, 10-19.
40. Loddenkemper R, Sagebiel D, Brendel A. (2002). Strategies against multidrug-resistant tuberculosis. Eur Respir J Suppl, 36, 66s-77s.
41. Loddenkemper R, Hauer B. (2010). Drug-resistant tuberculosis: a worldwide epidemic poses a new challenge. Dtsch Arztebl Int, 107(1-2), 10-19.
42. Loïez-Durocher C, Vachée A, Lemaitre N. (2000). Drug resistance in Mycobacterium tuberculosis: diagnostic methods. Ann Biol Clin (Paris), 58, 291-297.
43. Luetkemeyer AF, Charlebois ED, Flores LL, Bangsberg DR, Deeks SG, Martin JN, Havlir DV. (2007). Comparison of an interferongamma release assay with tuberculin skin testing in HIV-infected individuals. Am J Respir Crit Care Med, 175, 737-742.
44. Masood MI, Qadir MI, Shirazi JH, Khan IU. (2011). Beneficial effects of lactic acid bacteria on human beings. Crit Rev Microbiol, 37, 91-98.
45. Mendez JC. (2001). Multi drug resistance in tuberculosis and the use of PCR for defining molecular markers of resistance. Jacksonville Medicine. Available at: http://www.dcmsonline.org/jaxmedicine/2001journals/Feb2001/ TBresistance.htm.
46. Menzies D, Benedetti A, Paydar A, Martin I, Royce S, Pai M, Vernon A, Lienhardt C, Burman W. (2009). Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis. PLoS Med, 6, e1000146.
47. Miotto P, Saleri N, Dembelé M, Ouedraogo M, Badoum G, Pinsi G, Migliori GB, Matteelli A, Cirillo DM. (2009). Molecular detection of rifampin and isoniazid resistance to guide chronic TB patient management in Burkina Faso. BMC Infect Dis, 9, 142.
48. Morris S, Bai GH, Suffys P, Portillo-Gomez L, Fairchok M, Rouse D. (1995). Molecular mechanisms of multiple drug resistance in clinical isolates of Mycobacterium tuberculosis. J Infect Dis, 171, 954-960.
49. Naz S, Qadir MI, Ali M, Janbaz KH. (2012). Nanotecnology for imaging and drug delivery in cancer. J Chem Soc Pak, 34(1), 107-111.
50. Nisar L, Qadir MI, Malik SA, Tabassum N. (2011). Characterization of the immunodominant regions within gp41 of env gene of HIV in Pakistan. J Chem Soc Pak, 33(4), 545-548.
51. O'Brien RJ. (1994). Drug-resistant tuberculosis: etiology, management and prevention. Semin Respir Infect, 9, 104-112.
52. Pablos-Mendez A, Gowda DK, Frieden TR. (2002). Controlling multidrug-resistant tuberculosis and access to expensive drugs: a rational framework. Bull World Health Organ, 80, 489-95; discussion 495.
53. Pablos-Méndez A, Raviglione MC, Laszlo A, Binkin N, Rieder HL, Bustreo F, Cohn DL, Catherina SB, Weezenbeek L, Kim SJ, Chaulet P, Nunn P. (1998). Global surveillance for antituberculosis-drug resistance, 1994-1997. N Engl J Med, 338, 1641-1649.
54. Paramasivan CN, Rehman F, Wares F, Sundar Mohan N, Sundar S, Devi S, Narayanan PR. (2010). First-and second-line drug resistance patterns among previously treated tuberculosis patients in India. Int J Tuberc Lung Dis, 14, 243-246.
55. Putman M, van Veen HW, Konings WN. (2000). Molecular properties of bacterial multidrug transporters. Microbiol Mol Biol Rev, 64, 672-693.
56. Qadir MI, Malik SA. (2010). HIV fusion inhibitors. Rev Med Virol, 20, 23-33.
57. Qadir MI, Malik SA. (2011). Genetic variation in the HR region of the env gene of HIV: A perspective for resistance to HIV fusion inhibitors. AIDS Res Hum Retroviruses, 27, 57-63.
58. Qadir MI, Malik SA, Nisa TU, Tabassum N, Ali S, Nisar N. (2010). Characterization of HR region of gp41 of HIV. Int J Agric Biol, 12, 456-458.
59. Rattan A, Kalia A, Ahmad N. (1998). Multidrug-resistant Mycobacterium tuberculosis: molecular perspectives. Emerging Infect Dis, 4, 195-209.
60. Reichman LB. (1994). The challenge of drug-resistant tuberculosis. Cleve Clin J Med, 61, 431-437.
61. Reichman LB. (1996). Multidrug resistance in the world: the present situation. Chemotherapy, 42 Suppl 3, 2-9; discussion 30.
62. Rossetti ML, Valim AR, Silva MS, Rodrigues VS. (2002). Resistant tuberculosis: a molecular review. Rev Saude Publica, 36, 525-532.
63. Segal-Maurer S, Urban C, Rahal JJ Jr. (1996). Current perspectives on multidrug-resistant bacteria. Epidemiology and control. Infect Dis Clin North Am, 10, 939-957.
64. Shah NS, Wright A, Drobniewski F. (2005). Extreme drug resistance in tuberculosis "XDR-TB": global survey of supranational reference laboratories for Mycobacterium tuberculosis with resistance to second-line drugs. Int J Tuberc Lung Dis, 9(Suppl 1), S77.
65. Sharma SK, Mohan A. (2006). Multidrug-resistant tuberculosis: a menace that threatens to destabilize tuberculosis control. Chest, 130, 261-272.
66. Small PM, Shafer RW, Hopewell PC, Singh SP, Murphy MJ, Desmond E, Sierra MF, Schoolnik GK. (1993). Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection. N Engl J Med, 328, 1137-1144.
67. Telzak EE, Chirgwin KD, Nelson ET, Matts JP, Sepkowitz KA, Benson CA, Perlman DC, El-Sadr WM. (1999). Predictors for multidrugresistant tuberculosis among HIV-infected patients and response to specific drug regimens. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG), National Institutes for Health. Int J Tuberc Lung Dis, 3, 337-343.
68. Tomioka H, Namba K. (2006). Development of antituberculous drugs: current status and future prospects. Kekkaku, 81, 753-774.
69. Weltman AC, Rose DN. (1994). Tuberculosis susceptibility patterns, predictors of multidrug resistance, and implications for initial therapeutic regimens at a New York City hospital. Arch Intern Med, 154, 2161-2167.
70. World Health Organization. (2010). Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. http://whqlibdoc.who.int/ publications/2011/9789241500708-eng.pdf (Accessed on January 18, 2011).